Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus BSL_PS71 for Streptococcus Agalactiae in Vaginal Mucosa
NCT04165551Phase 1Terminated
- Sponsor
- LGC Biosearch Technologies
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lactobacillus BSL_PS71 in Streptococcus agalactiae infection (GBS) (2 arms), sponsored by LGC Biosearch Technologies. Primary endpoint: Detection of Streptococus agalactiae in vaginal exudate at 8 weeks. Started Oct 2019; status: terminated.
02
Drugs
Lactobacillus BSL_PS71
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on NCT04165551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165551.